Clinical application of pharmacogenetics in gastrointestinal diseases.
As knowledge of the human genome grows, there will be a direct impact on the management of specific diseases. Within gastroenterology and hepatology, there has been a change in the understanding of how variations or mutations in genes involved in drug metabolism or disease pathophysiology affect response to therapy. This review discusses the application of clinical pharmacogenetics to the following diseases and disorders: inflammatory bowel disease, Helicobacter pylori infections, gastroesophageal reflux disease, irritable bowel syndrome, functional dyspepsia, liver transplantation and colon cancer. Although only a few genotyping tests are regularly used in clinical practice, it is anticipated that studies will propel the routine use of many of the tests described in this review, in the future.
Saito
Yuri A
YA
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Clinical Enteric Neuroscience Translational and Epidemiological Research, Charlton 8-110, 200 First Street SW, Rochester, MN 55905, USA.
Camilleri
Michael
M
D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D008297:Male; D010597:Pharmacogenetics / Q000639:trends*; D010599:Pharmacokinetics; D011110:Polymorphism, Genetic
D000970:Antineoplastic Agents